Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
1.500
-0.140 (-8.54%)
Aug 14, 2025, 2:12 PM - Market open
Canopy Growth Revenue
Canopy Growth had revenue of 72.13M CAD in the quarter ending June 30, 2025, with 8.94% growth. This brings the company's revenue in the last twelve months to 274.92M, down -4.24% year-over-year. In the fiscal year ending March 31, 2025, Canopy Growth had annual revenue of 269.00M, down -9.47%.
Revenue (ttm)
274.92M CAD
Revenue Growth
-4.24%
P/S Ratio
1.96
Revenue / Employee
286,372 CAD
Employees
960
Market Cap
395.46M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
Mar 31, 2023 | 333.25M | -142.45M | -29.94% |
Mar 31, 2022 | 475.70M | -70.95M | -12.98% |
Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CGC News
- 2 days ago - Canopy Growth Rallies On News Of Possible Rescheduling From Trump - Seeking Alpha
- 3 days ago - Cannabis stocks soar on Trump reclassification speculation - Invezz
- 3 days ago - Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification - CNBC
- 5 days ago - Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year - Business Wire
- 7 days ago - Best Canadian Cannabis Penny Stocks Under $5 to Watch Now - MarijuanaStocks
- 9 days ago - Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia - Business Wire
- 14 days ago - Canopy Growth Appoints Miles Worne as Managing Director of European Markets - Business Wire